Alkermes plc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
Alkermes plc. (ALKS) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $292.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2016-02-25
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2015 was $292.00K, a 96.23% decline from fiscal 2014.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2014 was $7.74M.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2012 was $372.00K, a 65.33% increase from fiscal 2011.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|
| 2015-12-31 | $292.00K 10-K · filed 2016-02-25 | |
| 2014-12-31 | $7.74M 10-K · filed 2016-02-25 | |
| 2013-12-31 | $8.22M 10-K · filed 2016-02-25 | |
| 2013-03-31 | $0.00 10-K · filed 2015-02-24 | |
| 2012-03-31 | $372.00K 10-KT · filed 2014-02-27 | |
| 2011-03-31 | $225.00K 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |